Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SOD1 | P00441 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1433032 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL485571 | 0.95 | NPSR1 (0.48) | NPSR1CYP4F2CYP4A11LMNAMAPT | |
| Hydrochloric Acid SCHEMBL644319 | 0.93 | NPSR1 (0.47) | NPSR1CYP4F2CYP4A11LMNAMAPT | |
| Hydrochloric Acid SCHEMBL1809798 | 0.93 | NPSR1 (0.47) | NPSR1CYP4F2CYP4A11LMNAMAPT | |
| Hydrochloric Acid SCHEMBL5196791 | 0.93 | NPSR1 (0.47) | NPSR1CYP4F2CYP4A11LMNAMAPT | |
| Hydrochloric Acid SCHEMBL1115400 | 0.93 | NPSR1 (0.47) | NPSR1CYP4F2CYP4A11LMNAMAPT | |
| SCHEMBL331908 | 0.93 | NPSR1 (0.50) | NPSR1CYP4F2CYP4A11LMNAMAPT | |
| SCHEMBL1809800 | 0.91 | NPSR1 (0.48) | NPSR1CYP4F2CYP4A11LMNAMAPT | |
| SCHEMBL28766822 | 0.91 | NPSR1 (0.48) | NPSR1CYP4F2CYP4A11LMNAMAPT | |
| SCHEMBL1772581 | 0.91 | NPSR1 (0.48) | NPSR1CYP4F2CYP4A11LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12209081-B2 | Heterocycle derivatives for treating TRPM3 mediated disorders | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-01-28 | — | — | US | disclosed |
| CN-119372649-A | Compatible display panel aluminum etching solution, and preparation method and application thereof | 浙江奥首材料科技有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-115232125-B | Polysubstituted benzene immunomodulatory compounds, composition and application thereof | 杭州和正医药有限公司 | 2024-06-18 | — | — | CN | disclosed |
| WO-2024067566-A1 | SATURATED RING DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PHARMACEUTICAL USE THEREOF | 苏州阿尔脉生物科技有限公司 | 2024-04-04 | — | — | WO | disclosed |
| CN-117800894-A | Saturated cyclic derivative, pharmaceutical composition containing same and medical application of saturated cyclic derivative | 苏州阿尔脉生物科技有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-116761796-A | Aryl derivatives for the treatment of TRPM3 mediated disorders | 勒芬天主教大学 | 2023-09-15 | — | — | CN | disclosed |
| EP-4196466-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | Akebia Therapeutics Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
| CN-115232125-A | Multi-substituted benzene immunomodulatory compounds, compositions and uses thereof | 杭州和正医药有限公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-112812113-B | Immunomodulatory compounds, compositions and uses thereof | 杭州和正医药有限公司 | 2022-09-20 | — | — | CN | disclosed |
| EP-4038052-A2 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | Domain Therapeutics (FR) | 2022-08-10 | — | — | EP | disclosed |
| US-6420380-B2 | FOR TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-07-16 | — | — | US | disclosed |
| US-6410531-B1 | FOR THERAPY OF HEPATITIS C VIRUS (HCV) INFECTION | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-06-25 | — | — | US | disclosed |
| US-20020037998-A1 | Hepatitis C inhibitor tri-peptides | LLINAS-BRUNET MONTSE (CA) | 2002-03-28 | — | — | US | disclosed |
| US-20020016442-A1 | Hepatitis C inhibitor tri-peptides | LLINAS-BRUNET MONTSE (CA) | 2002-02-07 | — | — | US | disclosed |
| US-6329417-B1 | RACEMATES, DIASTEREOISOMERS AND OPTICAL ISOMERS; PROTEASE INHIBITOR PEPTIDE ANALOG | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2001-12-11 | — | — | US | disclosed |
| US-6329379-B1 | OLIGOPEPTIDES FOR INHIBITING HEPATITIS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2001-12-11 | — | — | US | disclosed |
| US-6323180-B1 | PROTEASE INHIBITORS; INHIBIT REPLICATION OF HEPATITIS C VIRUS | BOEHRINGER INGELHEIM (CANADA) LTD (CA) | 2001-11-27 | — | — | US | disclosed |
| US-6268207-B1 | RESOLUTION OF ENANTIOMERS FROM A MIXTURE OF (1R,2S)/(1S,2S)-1-AMINO-2-VINYLCYCLOPROPYL CARBOXYLIC ACID METHYL ESTER COMPRISING THE STEP OF TREATING SAID MIXTURE WITH AN ESTERASE TO OBTAIN THE CORRESPONDING (1R,2S) ENANTIOMER | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2001-07-31 | — | — | US | disclosed |
| US-4570014-A | Cycloalkanecarboxylic acid compounds | BAYER AKTIENGESELLSCHAFT (DE) | 1986-02-11 | — | — | US | disclosed |
| US-4554017-A | Method and compositions for regulating plant growth using cycloalkane-carboxylic acid compounds | BAYER AKTIENGESELLSCHAFT (DE) | 1985-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209081-B2 | Heterocycle derivatives for treating TRPM3 mediated disorders | TRPM4, TRPM6, TRPM2 | NPSR1 507/4885CYP4F2 3261/4885CYP4A11 3126/4885 |
| US-20020037998-A1 | Hepatitis C inhibitor tri-peptides | LIPC, HAVCR2, HCCS | NPSR1 627/4885CYP4F2 1871/4885CYP4A11 335/4885 |
| US-20020016442-A1 | Hepatitis C inhibitor tri-peptides | HAVCR2, LIPC, HCCS | NPSR1 831/4885CYP4F2 1395/4885CYP4A11 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.